Scinai Immunotherapeutics's three largest insider shareholders as of September 09, 2026 are Amir Reichman (Chief Executive Officer, 71.16Mn shares), Mark Germain (Director, 12.00Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Amir Reichman | Chief Executive Officer | 71,163,760 | 0 | 71,163,760 | 85.6% | 18 Jun, 2026 |
| 2 | Mark Germain | Director | 12,000,000 | 0 | 12,000,000 | 14.4% | 18 Jun, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 16 Jun, 2026 | Amir Reichman | Chief Executive Officer | Acquired A | 400,000,000 | $0.00 | $0 | 71,163,760 | Direct |
| 16 Jun, 2026 | Mark Germain | Director | Acquired A | 120,000,000 | $0.00 | $0 | 12,000,000 | Direct |